Active substanceInsulin DegloudekInsulin Degloudek
Similar drugsTo uncover
  • Tresiba® Penphill®
    solution PC 
    Novo Nordisk A / S     Denmark
  • Tresiba® FlexTech®
    solution PC 
    Novo Nordisk A / S     Denmark
  • Dosage form: & nbsphypodermic solution
    Composition:

    In 1 ml of the drug contains:

    For a dosage of 100 U / ml:

    active substance: Insulin degludec 100 ED (3.66 mg);

    Excipients: glycerol 19.6 mg, phenol 1.5 mg, metacresol 1.72 mg, zinc 32.7 μg (zinc acetate 109.7 μg), hydrochloric acid / sodium hydroxide (for pH correction), water for injection up to 1 ml.

    The pH of the solution is 7.6.

    One syringe pen contains 3 ml of a solution equivalent to 300 units.

    The syringe-pen allows you to enter up to 80 units per injection in steps of 1 unit.

    For a dosage of 200 U / ml:

    active substance: Insulin degludec 200 ED (7.32 mg);

    Excipients: glycerol 19.6 mg, phenol 1.5 mg, metacresol 1.72 mg, zinc 71.9 μg (zinc acetate 241.4 μg), hydrochloric acid / sodium hydroxide (for pH correction), water for injection up to 1 ml.

    The pH of the solution is 7.6.

    One syringe pen contains 3 ml of a solution equivalent to 600 units.

    The syringe-pen allows you to enter up to 160 units per injection with a step of 2 units.

    One unit of insulin degloudek contains 0.0366 mg of anhydrous salt-free insulin degludec.

    One unit of insulin degloudek (ED) corresponds to one international unit (ME) of human insulin, one unit of insulin detemir or insulin glargine.

    Description:

    A clear, colorless solution.

    Pharmacotherapeutic group:hypoglycemic agent - long-acting insulin analog
    ATX: & nbsp

    A.10.A.E.   Insulins and their long-acting analogues

    A.10.A.E.06   Insulin degludek

    Pharmacodynamics:

    The drug Tresiba® FlexTech® is a basal analogue of human insulin of super-long-acting action; after subcutaneous injection, it forms soluble multiexamers in the subcutaneous depot, from which there is a continuous and prolonged absorption of insulin degludec into the bloodstream, which provides an ultra-long, flat profile of action and a stable hypoglycemic effect of the drug. During the 24-hour monitoring period of the hypoglycemic effect of the drug in patients who received insulin degludec once a day, Tresiba® Flex Tach®, in contrast to insulin glargine, showed a uniform volume of distribution between action in the first and second 12-hour periods (AUCGIR,0-12h,ss/ AUCGIR,total,ss = 0,5).

    The duration of the drug Tresiba® Flex Tach® is more than 42 hours within the therapeutic range of doses.The equilibrium concentration of the drug in the blood plasma is achieved 2-3 days after the administration of the drug.

    Insulin degludec in a state of equilibrium concentration demonstrates a significantly lower (4-fold) comparison with insulin glargine variability in daily profiles of hypoglycemic action, which is estimated from the value of the coefficient of variabilityCV) to study the hypoglycemic effect of the drug during a single dosing interval (AUCGIR,t,ss) and in within the time frame of 2 to 24 hours (AUCGIR,2-24h,ss), see Table 1.

    Table 1. The variability of the daily profiles of the hypoglycemic action of the drug Tresib® and insulin glargine in a state of equilibrium concentration in patients with type 1 diabetes mellitus.

    Insulin

    degloudek

    (N26)

    (CV%)

    Insulin

    glargine

    (N27)

    (CV%)

    Variability of daily profiles of hypoglycemic action during one dosing interval (AUCGIR,t,ss)

    20

    82

    Variability of daily profiles of hypoglycemic action during the time interval from 2 to 24 hours (AUCGiR,2-24h)

    22

    92

    CV: coefficient of intra-individual variability in%

    SS: Concentration of the drug in the equilibrium state

    AUCGiR,2-24h : a metabolic effect in the last 22 hours of the dosing interval (i.e., there is no effect on it of intravenous insulin administered during the introductory period of the clamp study).

    A linear relationship between an increase in the dose of the drug Tresiba® Flex Tach® and its general hypoglycemic effect has been proved.

    Both Tresib®® Flex Tach®®-100 ED / ml and 200 U / ml show a comparable total hypoglycemic effect when each of the two dosages is administered at the same total dose.

    In the studies, there was no clinically significant difference in the pharmacodynamics of the drug Tresib ® between elderly patients and older patients of a young age.

    Clinical efficacy and safety

    11 international randomized open clinical trials were conducted Treat-to-Target ("cure to goal" strategy) of 26 and 52 weeks in parallel groups, which included a total of 4,275 patients (1102 patients with type 1 diabetes and 3,173 patients with type 2 diabetes) who received Tresiba® .

    The effectiveness of the drug Tresiba® was studied in patients with type 1 diabetes who had not received insulin before, and with type 2 diabetes mellitus,who received insulin therapy, in a fixed or flexible dosage regimen of Tresib®. The lack of superiority of the reference drugs (insulin detemir and insulin glargine) over the preparation of Tresiba® with respect to the reduction of the indicator HbA1c from the moment of inclusion to the end of the study. The exception was the drug sitagliptin, in comparison with which the preparation of Tresiba® showed its statistically significant superiority with respect to the decrease in the HbA1C.

    The results of the clinical study (the "treat to the target" strategy) for the initiation of insulin therapy in patients with type 2 diabetes showed a 36% decrease in the incidence of confirmed episodes of nocturnal hypoglycemia (defined as episodes of hypoglycemia that occurred between day zero and six o'clock in the morning , confirmed by the result of measuring the concentration of blood plasma glucose <3,1 mmol / l, or evidence that the patient needed third-party care to restore the condition) against the backdrop of daily administration of Tresiba® once daily in combination with oral hypoglycemic medications (PGHP) compared with that with insulin glargine also in combination with PGHP .The results of the clinical study (the "treat up to the target" strategy) for baseline bolus insulin regimens in patients with type 2 diabetes showed a lower overall risk for hypoglycemic episodes and night hypoglycemia compared with the use of Tresib® as compared with insulin glargine .

    The results of a prospective meta-analysis of data from seven pre-clinical clinical trials involving patients with type 1 and type 2 diabetes demonstrated the benefits of treatment with Tresiba® with a lower glargine compared with insulin therapy, frequency of development in patients of episodes of confirmed hypoglycemia and episodes of confirmed nocturnal hypoglycemia. A decrease in the incidence of episodes of hypoglycemia during treatment with Tresiba® was achieved with a lower average fasting plasma glucose than with insulin glargine.

    Table 2 Results of meta-analysis of data on episodes of hypoglycemia

    The calculated risk ratio (insulin degludec / insulin glargine)

    Episodes of confirmed hypoglycemiaa

    Total

    Night

    Diabetes mellitus type 1 + type 2 (general data)

    0,91*

    0,74*

    Dose maintenance period b

    0,84*

    0,68*

    Elderly patients> 65 years of age

    0,82

    0,65*

    Type 1 diabetes mellitus

    1,10

    0,83

    Dose maintenance period b

    1,02

    0,75*

    Diabetes mellitus type 2

    0,83*

    0,68*

    Dose maintenance period b

    0,75*

    0,62*

    Only basal therapy in patients who had not previously received insulin

    0,83*

    0,64*

    * Statistically significant

    a Confirmed hypoglycemia is an episode of hypoglycemia, confirmed by a blood glucose concentration measurement of <3.1 mmol / l, or evidence that the patient needed third-party care to restore the condition. Confirmed night hypoglycemia is a hypoglycemia that occurred during the time of day between zero hours and six o'clock in the morning.

    b Episodes of hypoglycemia after the 16th week of therapy

    There was no clinically significant formation of antibodies to insulin after treatment with Tresib® Flex Tach® for an extended period of time.

    Pharmacokinetics:

    Absorption

    The super-long action of insulin degludec is due to the specially created structure of its molecule. After subcutaneous injection, the formation of soluble stable multi-hexamers, which create a depot of insulin in the subcutaneous fat.Multiexameres gradually dissociate, releasing insulin degludec monomers, resulting in a slow and prolonged delivery of the drug into the blood.

    The equilibrium concentration of the drug Tresiba in blood plasma is achieved 2-3 days after the administration of the drug.

    The effect of insulin degludec for 24 hours with its daily administration once a day is evenly distributed between the first and second 12-hour intervals (AUCGiR, 0-12h, ss/ AUCGIR,t,ss = 0,5).

    Distribution

    The relationship of insulin degludec with plasma proteins (albumin) is> 99%.

    Metabolism

    The breakdown of insulin degludec is similar to that of human insulin; all formed metabolites are inactive.

    Excretion

    Half-life after subcutaneous injection of the drug Tresiba® Flex Tach® is determined by the rate of its absorption from the subcutaneous tissue. The half-life of the drug Tresiba® FlexTech® is approximately 25 hours and does not depend on the dose.

    Linearity

    With subcutaneous administration, the total plasma concentrations were proportional to the administered dose in the therapeutic dose range. When directly comparing the two forms of outputof the preparation Tresib® FlexTach® - 100 U / ml and 200 U / ml, data on their bioequivalence to the established requirements were obtained (based on the data obtained for AUCIDeg,t,ss and Cmax,IDeg,ss).

    Special patient groups

    There were no differences in the pharmacokinetic properties of the Tresib ® Flex-Tach ® drug depending on the sex of the patients.

    Patients of advanced age, patients of different ethnic groups, patients with impaired renal or hepatic function

    There were no clinically significant differences in the pharmacokinetics of insulin degludec between elderly and young patients, between patients of different ethnic groups, between patients with impaired renal and hepatic function and healthy patients.

    Children and teens

    The pharmacokinetic properties of insulin degludec when tested in children (6-11 years) and adolescents (12-18 years) with type 1 diabetes are comparable to those in adult patients. Against the background of a single administration of the drug to patients with type 1 diabetes mellitus it was demonstrated that the total effect of the dose of the drug in children and adolescents is higher in comparison with that in adult patients.

    Pre-clinical safety data

    Preclinical data based on studies of pharmacological safety, toxicity of repeated doses, carcinogenic potential, toxic effect on reproductive function, did not reveal any hazard of insulin deglucose for humans.

    The ratio of metabolic and mitogenic activities of insulin deglucose is similar to that of human insulin.

    Indications:

    Diabetes mellitus in adults.

    Contraindications:

    Increased individual sensitivity to the active substance or any of the auxiliary components of the drug.

    Children under the age of 18, the period of pregnancy and breastfeeding (clinical experience of the drug in children, women during pregnancy and breastfeeding is absent).

    Pregnancy and lactation:

    Pregnancy

    The use of the drug Tresiba® FlexTach® during pregnancy is contraindicated, since the clinical experience of its use during pregnancy is absent. Studies of reproductive function in animals showed no difference between insulin degludec and human insulin in terms of embryotoxicity and teratogenicity.

    Breastfeeding period

    The use of the drug Tresiba® FlexTach® during the period of breastfeeding is contraindicated, since the clinical experience of its use in lactating women is absent.

    Studies in animals have shown that in rats insulin degluedek is excreted in breast milk, the concentration of the drug in breast milk is lower than in blood plasma. It is not known whether insulin degluedek with breast milk of women.

    Fertility

    In animal studies, there was no adverse effect of insulin deglutecus on fertility.

    Dosing and Administration:

    The drug Tresiba® FlexTech® is an analogue of insulin of super-long-acting action.

    The drug is administered subcutaneously once a day at any time of the day, but it is preferable to administer the drug at the same time every day.

    In patients with type 2 diabetes mellitus, the drug Tresiba® Flex Tach® can be used either as monotherapy or in combination with PGHP or bolus insulin (see subsection Pharmacodynamics).

    Patients with type 1 diabetes mellitus are prescribed Tresiba® Flex Tach® in combination with short / ultrashort insulin to cover the need for prandial insulin.

    The dose of the drug Tresiba® Flex Tach® should be determined individually according to the patient's needs. To optimize the control of glycemia, it is recommended to correct the dose of the drug based on the fasting plasma glucose values.

    As with any form of insulin, the dose adjustment of Tresib® FlexTech® may also be necessary if the patient's physical activity is increased, his usual diet changes, or if he has a concomitant disease.

    The initial dose of the drug Tresiba® FlexTech®

    Patients with type 2 diabetes mellitus

    The recommended initial daily dose of the drug Tresiba® FlexTach® is 10 units, with the subsequent selection of an individual dose of the drug.

    Patients with type 1 diabetes mellitus

    The drug Tresiba® FlexTech® is prescribed once a day in combination with prandial insulin, which is administered together with a meal, followed by the selection of an individual dose of the drug.

    Translation from other insulin preparations

    It is recommended that the blood glucose concentration be closely monitored during the transfer and in the first weeks of the appointment of the new drug.It may be necessary to correct the concomitant hypoglycemic therapy (dose and time of administration of insulin preparations of short and ultrashort action or dose of PGHP).

    Patients with type 2 diabetes mellitus

    When transferring to a preparation of Tresiba® FlexTech® patients with type 2 diabetes mellitus on basal or basal-bolus insulin regimens or on a regimen of ready-mixed insulin / self-mixed insulin preparations, the dose of Tresiba® FlexTech® should be calculated on the basis of the dose of basal insulin , which the patient received before his transfer to a new type of insulin, according to the principle of "unit per unit," and then adjusted in accordance with the individual needs of the patient.

    Patients with type 1 diabetes mellitus

    In most patients with type 1 diabetes mellitus, when switching from any basal insulin to the Tresib® FlexTech® preparation, the "unit per unit" principle is used based on the basal insulin dose that the patient received before the transition, then the dose is adjusted according to his individual needs. In patients with type 1 diabetes mellitus,which at the time of transfer to therapy with Tresib® Flex Tach® were on insulin therapy with basal insulin in a mode of twice daily administration, or in patients with a HbA1FROM <8%, the dose of Tresiba® Flex Tach® should be adjusted on an individual basis. It may be necessary to reduce the dose followed by an individual dose selection based on glycemic parameters.

    Flexible dosing regimen

    Based on the patient's needs, the Tresiba® FlexTech® preparation allows to change the time of its administration (see subsection "Pharmacodynamics "). The interval between injections should be at least 8 hours.

    Those patients who forget to enter the dose of insulin in time, it is recommended to enter the dose as soon as they have found it, and then return to their usual time of a daily single injection of the drug.

    Tresib®® Flex Tach® 100 U / ml and Tresib®® Flex Tach® 200 U / ml Tresib®® Flex Tach® is available in two dosages. For both dosages, the set of the required dose of the drug is carried out in units. However, the dose step differs between the two dosages of the Tresib®® FlexTech® preparation.

    • Tresiba® FlexTach® 100 ED / ml allows the administration of doses ranging from 1 to 80 U in steps of 1 unit in one injection.
    • Tresiba® Flex Tach® 200 U / ml allows the administration of doses of 2 to 160 U with 2 U steps in one injection. Insulin dose is contained in half the volume of the solution as compared with the preparations of basal insulin 100 U / ml.

    The dose counter shows the number of units regardless of dosage; not necessary Conduct a recalculation dose when transferring patients to a new dosage.

    Special patient groups

    Patients of advanced age (over 65 years)

    The drug Tresiba® FlexTach® can be used in elderly patients. The concentration of blood glucose should be carefully monitored and the insulin dose adjusted individually (see section Pharmacokinetics).

    Patients with kidney and liver failure

    The drug Tresiba® Flex Tach® can be used in patients with kidney and liver failure. The concentration of blood glucose should be carefully monitored and the insulin dose adjusted individually (see section Pharmacokinetics). Children and teens

    Existing pharmacokinetic data are presented in subsection Pharmacokinetics, but the efficacy and safety of Tresib® Flex Tach® in children and adolescents have not been studied, and recommendations on the dose of the drug in children have not been developed.

    Mode of application

    The drug Tresiba® FlexTech® is intended only for subcutaneous administration.

    The drug Tresiba® Flex Tach® can not be administered intravenously, as this can lead to the development of severe hypoglycemia. The drug Tresiba® Flex Tach® can not be administered intramuscularly, since in this case the absorption of the drug changes. The drug Tresiba® FlexTech® can not be used in insulin pumps.

    Tresib®® Flex Tach® is injected subcutaneously into the thigh, anterior abdominal wall, or shoulder area. You should constantly change injection sites within the same anatomical area to reduce the risk of developing lipodystrophy. Tresiba® FleksTach® preparation is a pre-filled pen syringe designed for use with disposable injection needles or NovoFine® NovoTvist®.

    Side effects:

    The most common side effect reported during the treatment with insulin degludec is hypoglycemia (see "Description of individual adverse reactions "). All of the side effects presented below, based on data from clinical trials, are grouped according to MedDRA and organ systems. The incidence of side effects is defined as: very often (≥1 / 10); often (≥1 / 100 to <1/10); infrequently (≥1 / 1,000 to <1/100); rarely (≥1 / 10,000 to <1 / 1,000), very rarely (<1 / 10,000) and unknown (impossible to estimate based on available data).

    System of organs

    Frequency

    Infringements from immune system

    Rarely - Hypersensitivity reactions

    Rarely - Hives

    Disorders from the metabolism and nutrition

    Often - Hypoglycaemia

    Disturbances from the skin and subcutaneous tissues

    Infrequently - Lipodystrophy

    General disorders and violations at the site of administration

    Often - Reactions at the site of administration

    Infrequently - Peripheral edema

    Description of individual adverse reactions

    Immune system disorders

    With the use of insulin preparations, it is possible to develop allergic reactions. Allergic reactions of the immediate type to the insulin preparation itself or the auxiliary components that make up it can potentially threaten the life of the patient.

    When using the drug Tresiba® FlexTech® hypersensitivity reactions (including swelling of the tongue or lips, diarrhea, nausea,a feeling of fatigue and skin itching) and hives are rarely seen.

    Hypoglycaemia

    Hypoglycemia can develop if the dose of insulin is too high in relation to the patient's need for insulin. Severe hypoglycemia can lead to loss of consciousness and / or convulsions, temporary or irreversible impairment of brain function up to a lethal outcome. Symptoms of hypoglycemia, as a rule, develop suddenly. They include cold sweats, pale skin, increased fatigue, nervousness or tremor, anxiety, unusual fatigue or weakness, impaired orientation, decreased concentration, drowsiness, severe hunger, visual impairment, headache, nausea, palpitations.

    Lipodystrophy

    Lipodystrophy (including lipohydrophy, lipoatrophy) can develop at the injection site. Adherence to the rules of changing the injection site within one anatomical area helps reduce the risk of this side reaction.

    Reactions at the site of administration

    In patients who received the drug Tresiba® FlexTech®, there were reactions at the injection site (hematoma, pain, local hemorrhage, erythema,nodules of connective tissue, swelling, discoloration of the skin, itching, irritation and compaction at the injection site). Most of the reactions at the site of administration are insignificant and temporary, and usually disappear when the treatment is continued.

    Children and teens

    Pharmacokinetic properties of the drug Tresiba® FlexTach® have been studied in children and adolescents under the age of 18 (see section Pharmacokinetics). Studies of the efficacy and safety of insulin degludec in children and adolescents have not been conducted.

    Special patient groups

    In clinical trials, no differences in the frequency, type or severity of adverse reactions between elderly patients and patients with impaired renal or hepatic function and the general population of patients have been identified.

    Overdose:

    A certain dose necessary for an insulin overdose has not been established, however hypoglycemia can develop gradually if the dose of the drug has been too high in comparison with the patient's need (see "Special instructions").

    - Light hypoglycemia the patient can eliminate himself by taking glucose or sugar-containing foods inside.Therefore, patients with diabetes are encouraged to constantly carry with them sugar-containing foods.

    - In case of severe hypoglycemiawhen the patient is unconscious, he should enter glucagon (from 0.5 to 1 mg) intramuscularly or subcutaneously (can be administered by a trained person), or intravenously a solution of dextrose (glucose) (can be administered only by a medical professional). It is also necessary to inject dextrose intravenously in the case if the patient does not regain consciousness 10 to 15 minutes after the administration of glucagon. After restoration of consciousness, the patient is recommended to take food rich in carbohydrates, to prevent the recurrence of hypoglycemia.

    Interaction:

    There are a number of drugs that affect the need for insulin.

    The need for insulin can reduce: oral hypoglycemic drugs, glucagon-like peptide-1 receptor agonists (GLP-1), monoamine oxidase inhibitors, non-selective beta-blockers, angiotensin converting enzyme inhibitors, salicylates, anabolic steroids and sulfonamides.

    The need for insulin can increase: oral hormonal contraceptives, thiazide diuretics, glucocorticosteroids, thyroid hormones, sympathomimetics, somatropin and danazol.

    Beta-blockers can mask symptoms of hypoglycemia.

    Octreotide / lanreotide can both increase and decrease the body's need for insulin.

    Ethanol (alcohol) can both enhance and reduce the hypoglycemic effect of insulin.

    Incompatibility

    Some drugs, when added to the drug Tresib® Flex Tach®, can cause its destruction.

    The drug Tresiba® FlexTach® should not be added to infusion solutions.

    Do not mix Tresiba® Flex Tach® with other medications.

    Special instructions:

    Hypoglycaemia

    If you miss a meal or an unplanned intensive physical exertion, the patient may develop hypoglycemia. Hypoglycemia can also develop if the insulin dose is too high in relation to the patient's need (see Sections Side effect and Overdose).

    After the compensation of carbohydrate metabolism (for example, with intensified insulin therapy), the symptoms typical for them, precursors of hypoglycemia, may change in patients,about which patients should be informed. Common symptoms-precursors can disappear with prolonged course of diabetes. Concomitant diseases, especially infectious and accompanied by fever, usually increase the body's need for insulin. Correction of the dose of the drug may also be required if the patient has concomitant diseases of the kidneys, liver or disorders of the adrenal, pituitary or thyroid gland function.

    As with other basal insulin preparations, recovery from hypoglycemia with Tresiba® FlexTech® may be delayed.

    Hyperglycaemia

    An insufficient dose of the drug or discontinuation of treatment can lead to the development of hyperglycemia or diabetic ketoacidosis. In addition, concomitant diseases, especially infectious diseases, can promote the development of hyperglycemic conditions and, accordingly, increase the body's need for insulin.

    Typically, the first symptoms of hyperglycemia appear gradually, within a few hours or days. These symptoms include: thirst, rapid urination, nausea, vomiting, drowsiness, redness and dryness of the skin, dry mouth, loss of appetite, odor of acetone in the exhaled air.With type 1 diabetes mellitus without appropriate treatment, hyperglycemia leads to the development of diabetic ketoacidosis and can lead to death.

    For the treatment of severe hyperglycemia, it is recommended that high-speed insulin be administered.

    Transfer of a patient from other insulin preparations

    Transfer of a patient to a new type or preparation of insulin of a new brand or other manufacturer should occur under strict medical supervision. The translation may require a dose adjustment.

    The simultaneous use of drugs of the thiazolidinedione group and insulin preparations

    Cases of chronic heart failure in the treatment of patients with thiazolidinediones in combination with insulin preparations have been reported, especially if such patients have risk factors for developing chronic heart failure. This fact should be taken into account when appointing patients a combination therapy with thiazolidinediones and the preparation of Tresiba® FlexTech®. In the appointment of such combination therapy, it is necessary to conduct medical examinations of patients to identify signs and symptoms of chronic heart failure, increase in body weight and the presence of peripheral edema.If the symptoms of heart failure worsen in patients, treatment with thiazolidinediones should be discontinued.

    Disturbances on the part of the organ of sight

    Intensification of insulin therapy with a sharp improvement in carbohydrate metabolism control may lead to a temporary deterioration in the state of diabetic retinopathy, while a prolonged improvement in glycemic control reduces the risk of progression of diabetic retinopathy.

    Prevention of accidental entanglement of insulin preparations

    The patient should be instructed to check the labeling on the label before each injection to avoid accidental administration of another dose or other insulin. Before each injection, patients should check the dose counter for the number of units typed in the syringe pen. Thus, only patients who can clearly distinguish the numbers on the dose counter can inject insulin themselves.

    It is necessary to inform visually impaired or visually impaired people that they always need the help of persons who do not have vision problems and are trained to work with a syringe pen.

    Antibodies to insulin

    With the use of insulin, the formation of antibodies is possible.In rare cases, the formation of antibodies may require a dose adjustment of insulin to prevent cases of hyperglycemia or hypoglycemia.

    Instructions for patients on the use of the drug Tresiba® FlexTech® solution for subcutaneous administration 100 U / ml

    Read these instructions carefully before using the pre-filled Tresib® FlexTouch® syringe pen.

    Use a syringe pen only after you learn to use it under the guidance of a doctor or nurse. Check the label on the syringe pen label to make sure it contains the Tresiba® FlexTech® 100 U / mL preparation, and then carefully examine the illustrations below that show the details of the syringe and needle.

    If you are visually impaired or you have serious vision problems and you can not distinguish the numbers on the dose counter, do not use a syringe pen without help. You can be helped by a person without visual impairment, trained in the correct use of a pre-filled Flex-Tach® pen. Tresiba® Flex Tach® 100 U / ml is a pre-filled syringe pen containing 300 units of insulin degludec.The maximum dose that you can set is 80 units in 1-step increments. The Tresib® Flex-Tach ® pen is designed for use with NovoFine® or NovoTvist® disposable needles up to 8 mm long. Needles are not included in the packaging.

    (!) Important information

    Pay attention to the information marked with such icons (!), It is very important for the safe use of the syringe pen.

    Tresiba® Flex Tach® 200 U / ml and needle is an example withm. Figure 1-2.

    1. Preparing the syringe pen for use

    A. Check the name and dosage on the label of the pen syringe to make sure it contains the Tresiba® Flex Tach® 100 ED / mL preparation. This is especially important if you use different types of insulin.

    Remove the cap from the syringe pen.

    C. Ensure that the insulin preparation in the syringe pen is clear and colorless. Look at the scale of the insulin balance. If the drug is cloudy, the pen can not be used.

    C. Take a new disposable needle and remove the protective sticker.

    D. Put the needle on the syringe pen and rotate it so that the needle fits tightly on the syringe pen.

    E. Remove the outer cap of the needle, but do not throw it away. You will need it after the injection is completed to safely remove the needle.

    F. Remove and discard the inner needle cap.If you try to put the inner cap back on the needle, you can prick.

    At the end of the needle, a drop of insulin may appear. This is normal, however, you all should check your insulin intake (see Figure 1 A-F).

    (!) For each injection, use a new needle to avoid clogging the needle, infecting, infecting and injecting the wrong dose of the drug.

    (!) Never use the needle if it is bent or damaged.

    2. Insulin intake check

    A.

    - Before each injection, check the intake of insulin. So you can be sure that the insulin dose is introduced completely

    - Dial 2 units of the drug by turning the dose selector. Make sure that the dose counter shows "2" (see Figure 2A).

    AT.

    Holding the syringe handle with the needle upwards, tap the top of the syringe handle several times with the tip of the finger, so that the air bubbles move upwards (see Fig. 2B).

    FROM.

    - Press the start button and hold it in this position until the dose counter returns to zero.

    "0" must stand in front of the dose indicator At the end of the needle, a drop of insulin should appear (see Fig. 2C).

    Sometimes a small air bubble may remain at the end of the needle, but it will not be injected.

    If a drop of insulin does not appear at the end of the needle, repeat steps 2A-2C, but no more than 6 times.If a drop of insulin does not appear, change the needle and repeat operations 2A-2C again.

    Do not use a syringe pen if a drop of insulin at the end of the needle has not appeared.

    (!) Before each injection, make sure that a drop of insulin appears on the tip of the needle. If a drop of insulin does not appear, the dose will not be given, even if the dosage counter moves

    3. Setting the dose

    A.

    - Before starting the injection, make sure that the dose counter is set to "0".

    "0" must be in front of the dosing indicator.

    - Rotate the dose selector set the dose assigned by the doctor.

    If you have set the wrong dose, you can turn the dose selector forwards or backwards until the correct dose is set. The maximum dose that you can set is 80 units (see Figure 3A).

    The dose selector sets the number of units. Only the dose counter and dose indicator show the number of units of insulin in the selected dose. The maximum dose you can set is 80 units. If the insulin residue in the syringe pen is less than 80 units, the dose counter will stop on the number of units of insulin that remains in the syringe pen.At each turn of the dose selector, clicks are heard, the sound of clicks depends on which way the dose selector is rotating (forward, backward or if the dialed dose exceeds the number of insulin units left in the pen). Do not count these clicks.

    (!) Before each injection, check how many units of insulin you have typed on the dose counter and the dose indicator

    Do not set the dose by the number of clicks.

    The scale of the insulin residue shows the approximate amount of insulin remaining in the syringe, so it can not be used to measure the dose of insulin

    4. Introduction of insulin

    A.

    - Insert the needle under the skin using the injection technique recommended by your doctor.

    - Make sure that the dose counter is in your field of vision.

    Do not touch the dose counter with your fingers - this may interrupt the injection.

    - Press the start button all the way down and hold it in this position until the dose counter shows "0".

    "0" must be exactly opposite the dose indicator. You can hear or feel a click.

    - After injection, leave the needle under the skin for at least 6 seconds. This will ensure the introduction of a full dose of insulin (see Figure 4A).

    AT.

    - Remove the needle from under the skin by pulling the syringe up (see Fig. 4B).

    If blood appears at the injection site, gently press a cotton swab into the injection site. Do not massage the injection site.

    After completing the injection, you can see a drop of insulin at the end of the needle.

    This is normal and does not affect the dose of the drug you entered.

    (!) Always check with the dose counter to know how many insulin units you have entered.

    Do not count the number of clicks. The dose counter will show the exact number of units.

    5. After the injection is completed

    A.

    - After placing the outer needle cap on a flat surface, insert the end of the needle into the cap, without touching it or until the tip of the needle.

    AT.

    - When the needle enters the cap, gently place the cap on the needle.

    - Unscrew the needle and discard it, observing the precautions.

    FROM

    - After each injection, put a cap on the syringe pen to protect the insulin contained in it from exposure to light (see Fig. 5A-C).

    Discard the needle after each injection, this will ensure a comfortable injection of insulin and prevent clogging of the needle. If the needle is clogged, you can not inject insulin.

    Dispose of the used syringe pen with the needle disconnected, as recommended by your doctor, nurse, pharmacist or according to local requirements

    (!) To avoid accidental pricking with a needle, never try to put the inner cap back on the needle

    (!) Remove the needle from the syringe-pen after each injection

    This will prevent clogging of the needle, infection, infection, leakage of insulin from the syringe pen and incorrect dosing

    6. How much insulin is left?

    A.

    - The scale of the insulin residue shows the approximate amount of insulin remaining in the syringe-pen.

    AT.

    - To find out how much insulin is left in your syringe pen, use a dose counter.

    Rotate the dose selector until the dose counter stops.

    If the dose counter shows a figure of 80, it means that at least 80 insulin units remain in your syringe pen.

    If the dose counter shows less than 80, this means that exactly the number of insulin units that was displayed on the dose counter remained in your syringe pen.

    - Rotate the dose selector in the opposite direction until the dose counter shows "0".

    - If the insulin remaining in the syringe pen is not enough to administer the full dose, you can enter the dose you need for two injections with the help of two syringes (see Fig. 6 AB).

    (!) Be very careful when calculating the remainder of the insulin dose you need to prevent an error.

    If you have doubts, better enter a full dose of insulin with a new syringe pen.

    (!) Important information

    - Always carry a syringe pen with you.

    - Always carry a spare syringe pen and new needles in case they are lost or damaged.

    - Keep the syringe-pen and needle out of reach of all, and especially for children, the place.

    - Never give your syringe pen and needle to it to others.

    - Persons caring for the patient should handle the used needles with extreme care to avoid accidental injections and infection.

    Care of the syringe pen

    - Do not leave a syringe pen in the car or any other place where it can be exposed to too high or too low temperatures.

    - Protect the syringe handle from getting on it dust, dirt and all kinds of liquids.

    - Do not wash the syringe handle, do not immerse it in liquid and do not lubricate it. If necessary, the syringe pen can be cleaned with a damp cloth moistened with a mild detergent.

    - Do not drop or hit the syringe handle on a hard surface.

    If you drop a syringe pen or doubt its serviceability, attach a new needle and check the intake of insulin before you inject.

    - Do not refill the syringe pen. Do not reuse an empty syringe pen.

    - Do not attempt to repair the syringe pen by itself or dismantle it.

    Instruction for patients on the use of the drug Tresiba® FlexTech® solution for subcutaneous administration 200 U / ml

    Read these instructions carefully before using the pre-filled Tresib® FlexTouch® syringe pen.

    Use a syringe pen only after you learn to use it under the guidance of a doctor or nurse. Check the label on the syringe pen label to make sure it contains the Tresib® Flex Tach® 200 U / ml preparation, and then carefully examine the illustrations below, which show the details of the syringe pens and needles.

    If you are visually impaired or you have serious vision problems and you can not distinguish the numbers on the dose counter, do not use a syringe pen without help.You can be helped by a person without visual impairment, trained in the correct use of a pre-filled Flex-Tach® pen. Tresiba® Flex Tach® 200 U / ml is a pre-filled syringe pen containing 600 units of insulin degludec. The maximum dose that you can set is 160 units in 2-ED increments. The dose counter shows the exact number of insulin units. You do not need to recalculate the dose. The Tresib® Flex-Tach ® pen is designed for use with NovoFine® or NovoTvist® disposable needles up to 8 mm long. Needles are not included in the packaging.

    (!) Important information

    Pay attention to the information marked with these icons, it is very important for the safe use of the syringe pen.

    Tresiba® Flex Tach® 200 U / ml and needle (example)

    1. Preparing the syringe pen for use

    A. Check the name and dosage on the label of the pen syringe to make sure it contains the Tresiba® Flex Tach® 200 ED / ml preparation. This is especially important if you use different types of insulin.

    Remove the cap from the syringe pen.

    C. Ensure that the insulin preparation in the syringe pen is clear and colorless. Look at the scale of the insulin balance.If the drug is cloudy, the pen can not be used.

    C. Take a new disposable needle and remove the protective sticker.

    D. Put the needle on the syringe pen and rotate it so that the needle fits tightly on the syringe pen.

    E. Remove the outer cap of the needle, but do not throw it away. You will need it after the injection is completed to safely remove the needle.

    F. Remove and discard the inner needle cap. If you try to put the inner cap back on the needle, you can prick.

    At the end of the needle, a drop of insulin may appear. This is normal, however, you still need to check the intake of insulin.

    (!) For each injection, use a new needle to avoid clogging the needle, infecting, infecting and injecting the wrong dose of the drug.

    (!) Never use the needle if it is bent or damaged.

    2. Checking for insulin A

    - Before each injection, check the intake of insulin. So you can be sure that the insulin dose is introduced completely

    - Dial 2 units of the drug by turning the dose selector. Make sure that the dose counter shows "2".

    AT.

    Holding the needle pen up with the needle, tap lightly on the top of the syringe pen several times with the tip of the finger so that the air bubbles move upward.

    FROM.

    - Press the start button and hold it in this position until the dose counter returns to zero.

    "O" should stand in front of the dose indicator At the end of the needle, a drop of insulin should appear.

    Sometimes a small air bubble may remain at the end of the needle, but it will not be injected.

    If a drop of insulin does not appear at the end of the needle, repeat steps 2A-2C, but no more than 6 times. If a drop of insulin does not appear, change the needle and repeat operations 2A-2C again.

    Do not use a syringe pen if a drop of insulin at the end of the needle has not appeared.

    (!) Before each injection, make sure that a drop of insulin appears on the tip of the needle. If a drop of insulin does not appear, the dose will not be given, even if the dosage counter will move.

    3. Setting the dose

    A.

    - Before starting the injection, make sure that the dose counter is set to "0".

    "0" must be in front of the dosing indicator.

    - Rotate the dose selector set the dose assigned by the doctor.

    - The dose counter shows the exact number of units of insulin.

    You do not need to recalculate the dose.

    If you have set the wrong dose, you can turn the dose selector forwards or backwards until the correct dose is set. The maximum dose you can set is 160 units.

    The dose selector sets the number of units. Only the dose counter and dose indicator show the number of units of insulin in the selected dose.

    The maximum dose you can set is 160 units. If the insulin residue in the syringe pen is less than 160 units, the dose counter will stop on the number of units of insulin that remains in the syringe pen. At each turn of the dose selector, clicks are heard, the sound of clicks depends on which way the dose selector is rotating (forward, backward or if the dialed dose exceeds the number of units of insulin remaining in the syringe pen). Do not count these clicks.

    (!) Before each injection, check how many units of insulin you have typed on the dose counter and dose indicator.

    Do not set the dose by the number of clicks.

    The scale of the insulin residue shows the approximate amount of insulin remaining in the syringe, so it can not be used to measure the dose of insulin.

    4. Introduction of insulin

    A.

    - Insert the needle under the skin using the injection technique recommended by your doctor.

    - Make sure that the dose counter is in your field of vision.

    Do not touch the dose counter with your fingers - this may interrupt the injection.

    - Press the start button all the way down and hold it in this position until the dose counter shows "0".

    "0" must be exactly opposite the dose indicator. You can hear or feel a click.

    - After injection, leave the needle under the skin for at least 6 seconds. This will ensure the introduction of a full dose of insulin.

    AT.

    - Remove the needle from under the skin by pulling the syringe up.

    If blood appears at the injection site, gently press a cotton swab into the injection site. Do not massage the injection site.

    After completing the injection, you can see a drop of insulin at the end of the needle.

    This is normal and does not affect the dose of the drug you entered.

    (!) Always check with the dose counter to know how many insulin units you have entered.

    Do not count the number of clicks. The dose counter will show the exact number of units

    5. After the injection is completed

    A.

    - After placing the outer needle cap on a flat surface, insert the end of the needle into the cap, without touching it or until the tip of the needle.

    AT.

    - When the needle enters the cap, gently place the cap on the needle.

    - Unscrew the needle and discard it, observing the precautions.

    FROM.

    - After each injection, wear on the pen cap to protect the insulin contained therein from light.

    Discard the needle after each injection, this will ensure a comfortable injection of insulin and prevent clogging of the needle. If the needle is clogged, you can not inject insulin.

    Dispose of the used syringe pen with the needle disconnected, as recommended by your doctor, nurse, pharmacist or according to local requirements.

    (!) To avoid accidental pricking with a needle, never try to put the inner cap back on the needle.

    (!) Remove the needle from the syringe pen after each injection.

    This will prevent clogging of the needle, infection, infection, leakage of insulin from the syringe pen and incorrect dosing

    6. How much insulin is left?

    A.

    - The scale of the insulin residue shows the approximate amount of insulin remaining in the syringe-pen.

    AT.

    - To find out how much insulin is left in your syringe pen, use a dose counter.

    Rotate the dose selector until the dose counter stops.

    If the dose counter shows a figure of 160, this means that at least 160 units of insulin remain in your syringe pen.

    If the dose counter shows less than 160, it means that in your syringe pen there was exactly that amount of insulin units that was displayed on the dose counter.

    - Rotate the dose selector in the opposite direction until the dose counter shows "0".

    - If the insulin remaining in the syringe-pen is not enough to introduce the full dose, you can enter the dose you need for two injections with the help of two syringes-pens.

    (!) Be very careful when calculating the remainder of the insulin dose you need to prevent an error.

    If you have doubts, better enter a full dose of insulin with a new syringe pen.

    (!) Important information

    - Always carry a syringe pen with you.

    - Always carry a spare syringe pen and new needles in case they are lost or damaged.

    - Keep the syringe-pen and needle out of reach of all, and especially for children, the place.

    - Never give your syringe pen and needle to it to others.

    - Persons caring for the patient should handle the used needles with extreme care to avoid accidental injections and infection.

    Care of the syringe pen

    - Do not leave a syringe pen in the car or any other place where it can be exposed to too high or too low temperatures.

    - Protect the syringe handle from getting on it dust, dirt and all kinds of liquids.

    - Do not wash the syringe handle, do not immerse it in liquid and do not lubricate it.If necessary, the syringe handle can be cleaned with a damp cloth moistened with a mild detergent.

    - Do not drop or hit the syringe handle on a hard surface.

    If you drop a syringe pen or doubt its serviceability, attach a new needle and check the intake of insulin before you inject.

    - Do not refill the syringe pen. Do not reuse an empty syringe pen.

    - Do not attempt to repair the syringe pen by itself or dismantle it.

    Effect on the ability to drive transp. cf. and fur:

    The ability of patients to concentrate and respond to the reaction may be impaired during hypoglycemia, which can be dangerous in situations where this ability is particularly necessary (for example, when driving vehicles or mechanisms).

    Patients should be advised to take measures to prevent the development of hypoglycemia in the management of vehicles. This is especially important for patients with absence or reduction in the severity of symptoms-harbingers of developing hypoglycemia or frequent episodes of hypoglycaemia.In these cases, the desirability of driving a vehicle should be considered.

    Form release / dosage:Solution for subcutaneous administration, 100 U / mL and 200 U / ml.
    Packaging:

    Solution for subcutaneous administration 200 U / ml in pre-filled FlexTach® syringes.

    3 ml in cartridges of glass 1 of hydrolytic class, sealed with stoppers with disks of halobutyl rubber / polyisoprene on one side and pistons of halobutyl rubber on the other side. The cartridge is sealed in a multi-dose disposable polypropylene syringe pen for multiple injections.

    For a dosage of 100 units / ml: 5 multi-dose disposable syringes with instructions for use in cardboard pack.

    For a dosage of 200 units / ml: 3 multi-dose disposable syringes with instructions for use in a cardboard pack.

    Storage conditions:

    Store at temperatures between 2 ° C and 8 ° C (in the refrigerator), but not near the freezer. Do not freeze.

    For the used or portable as a spare syringe pen: do not store in the refrigerator. Store at a temperature of no higher than 30 ° C for 8 weeks. After use, cover the syringe handle with a cap to protect it from light.

    Keep out of the reach of children.

    Shelf life:

    30 months.

    Do not use after expiry date.

    Terms of leave from pharmacies:On prescription
    Registration number:LP-002234
    Date of registration:18.09.2013
    Date of cancellation:2018-09-18
    The owner of the registration certificate:Novo Nordisk A / SNovo Nordisk A / S Denmark
    Manufacturer: & nbsp
    Representation: & nbspNOVO NORDISK TOVNOVO NORDISK TOVDenmark
    Information update date: & nbsp25.10.2015
    Illustrated instructions
    Instructions
    Up